ABOUT US
20/20 Onsite is a specialty vendor for sponsors and CROs conducting clinical trials with ocular endpoints, providing end-to-end ophthalmic trial consultation, clinical field execution, and ongoing support. Through a single-call accountability model, 20/20 Onsite helps sponsors de-risk ocular endpoint complexity and increase the likelihood of on-time, on-budget, protocol-adherent trial success.
Its proprietary point-of-need service delivery model reaches participants where they live, work, or congregate, reducing patient burden, improving retention, and supporting diverse enrollment strategies. Backed by proven expertise, nationwide experience at scale, and validated regulatory rigor, 20/20 Onsite has supported more than 45 clinical trials, served over 100,000 patients, and consistently delivered Net Promoter Scores above 95.
FEATURED ARTICLES
-
Dropout in retinal trials is often a logistical failure. Reducing travel burden and bringing specialized care to the patient can slash attrition rates and secure critical trial timelines.
-
High screen failure rates and patient dropout often stem from preventable imaging errors. Learn how proactive quality control and patient-centric logistics secure critical retinal trial data.
-
Standardizing ocular endpoint execution reduces participant dropout and eliminates data variability. Specialized oversight secures clinical timelines and ensures high-quality, submission-ready data.
-
Fluctuations in eye pressure measurements can jeopardize trial results. Learn how standardized execution and equipment calibration protect data integrity and regulatory credibility.
-
Explore how demographic shifts and retinal innovation are transforming ophthalmology trials, and why operational precision is the key to protecting data integrity in this high-growth sector.
-
Address transportation barriers to reduce protocol deviations and data gaps. Strategies that lower travel burden protect study timelines and improve visit adherence for better trial outcomes.
-
Sponsors are addressing patient dropout rates by shifting from reactive troubleshooting to proactive protocol designs that minimize participant burden.
-
Are minor inconsistencies in room setup and technician technique quietly compromising your study data? Learn how closing small operational gaps can prevent major downstream risks.
-
Learn how expert site initiation visit (SIV) planning masters complex endpoints like OCT and BCVA, eliminates data variability, and prevents the costly need for trial rescue.
-
Quickly assess clinical trial risks by evaluating site impact, patient safety, and budget tradeoffs. Turn high-pressure rescue scenarios into clear, actionable paths for your research team.
CONTACT INFORMATION
20/20 Onsite
29 Garden Street
Everett, MA 02149
UNITED STATES
Phone: 617-812-9453
Contact: Jessica McKenzie, Vice President, Life Sciences
FEATURED PRODUCTS
FEATURED CASE STUDIES
-
Community-based screenings identify undiagnosed eye disease at high rates, creating a scalable, high-trust pathway for early intervention and improved clinical research recruitment.
-
A Mobile Clinical Suite (MCS) proved to be the solution that Syneos Health needed to resolve their Phase 1 study trial challenges with comprehensive eye exams.
-
A contract research organization formed a partnership to address significant challenges during a Phase 1 clinical trial for a corneal disease treatment through the use of a Mobile Vision Pod.
-
20/20 Onsite, American Diabetes Association and Genentech collaborated on an event to provide immediate diagnostic services, including retinal imaging and visual acuity assessments, directly on-site.
-
This study highlights the transformative impact of point-of-need care on patient access, focusing on pediatric cystic fibrosis (CF) patients requiring essential eye exams.
-
Discover how the implementation of mobile vision clinics (MVCs) was used to enhance efficiency in a Phase 1 clinical trial.
-
During the COVID-19 pandemic, Applied Genetic Technologies Corporation (AGTC) faced significant hurdles in enrolling participants due to travel restrictions and site limitations.
-
Collaboration was key for Company W to overcome challenges with an FDA-mandated ocular substudy, including limited resources for ocular assessments and logistical difficulties